These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 22352370)
1. Pharmacokinetics of 250 μg anti-D IgG in the third trimester of pregnancy: an observational study. Tiblad E; Wikman A; Rane A; Jansson Y; Westgren M Acta Obstet Gynecol Scand; 2012 May; 91(5):587-92. PubMed ID: 22352370 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. Bichler J; Schöndorfer G; Pabst G; Andresen I BJOG; 2003 Jan; 110(1):39-45. PubMed ID: 12504934 [TBL] [Abstract][Full Text] [Related]
3. The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin. MacKenzie IZ; Roseman F; Findlay J; Thompson K; Jackson E; Scott J; Reed M BJOG; 2006 Jan; 113(1):97-101. PubMed ID: 16398777 [TBL] [Abstract][Full Text] [Related]
5. Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies. Tiblad E; Westgren M; Pasupathy D; Karlsson A; Wikman AT Acta Obstet Gynecol Scand; 2013 Sep; 92(9):1079-85. PubMed ID: 23750781 [TBL] [Abstract][Full Text] [Related]
6. Routine antenatal anti-D prophylaxis and patient compliance with the two-dose regimen. Chaffe B; Ford J; Bills V Transfus Med; 2007 Oct; 17(5):399-403. PubMed ID: 17903141 [TBL] [Abstract][Full Text] [Related]
7. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Koelewijn JM; de Haas M; Vrijkotte TG; Bonsel GJ; van der Schoot CE Transfusion; 2008 Aug; 48(8):1721-9. PubMed ID: 18507749 [TBL] [Abstract][Full Text] [Related]
9. Postdelivery levels of anti-D IgG prophylaxis in D- mothers depend on maternal body weight. Woelfer B; Schuchter K; Janisiw M; Hafner E; Philipp K; Panzer S Transfusion; 2004 Apr; 44(4):512-7. PubMed ID: 15043566 [TBL] [Abstract][Full Text] [Related]
10. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy. Okwundu CI; Afolabi BB Cochrane Database Syst Rev; 2013 Jan; (1):CD007885. PubMed ID: 23440818 [TBL] [Abstract][Full Text] [Related]
11. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative. Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics (PK) of S/D treated anti-D immunoglobulin after intramuscular injection in healthy volunteers: gender differences in PK. Jilma-Stohlawetz P; Reiter RA; Panzer S; Horvath M; Eppel W; Jilma B Transfus Apher Sci; 2005 Oct; 33(2):135-40. PubMed ID: 16112906 [TBL] [Abstract][Full Text] [Related]
13. [Guideline for prevention of RhD alloimmunizationin RhD negative women]. Lubušký M; Procházka M; Simetka O; Holusková I Ceska Gynekol; 2013 Apr; 78(2):132-3. PubMed ID: 23710977 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers. Bichler J; Spycher MO; Amstutz HP; Andresen I; Gaede K; Miescher S Transfus Med; 2004 Apr; 14(2):165-71. PubMed ID: 15113381 [TBL] [Abstract][Full Text] [Related]
19. Compliance with routine antenatal rhesus D prophylaxis and the impact on sensitisations: observations over 14 years. MacKenzie IZ; Findlay J; Thompson K; Roseman F BJOG; 2006 Jul; 113(7):839-43. PubMed ID: 16827770 [TBL] [Abstract][Full Text] [Related]
20. An increased risk for non allo-immunization related intrauterine fetal death in RhD-negative patients. Ben-David G; Sheiner E; Levy A; Erez O; Mazor M J Matern Fetal Neonatal Med; 2008 Apr; 21(4):255-9. PubMed ID: 18330822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]